CD274 and non-small cell lung carcinoma: When a BMI cutoff value of 22 kg/m2 was used, no significant difference was observed in the progression‐free survival (PFS) or overall survival (OS) between high‐ and low‐BMI groups among patients with NSCLC with high PD‐L1 expression (≥50%) who were treated with pembrolizumab as a first‐line therapy.